MDGL — Madrigal Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $10.12bn
- $9.48bn
- $958.40m
Annual cashflow statement for Madrigal Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -242 | -295 | -374 | -466 | -288 |
| Depreciation | |||||
| Non-Cash Items | 26.9 | 32.4 | 52.1 | 81.6 | 106 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 30.7 | 37.6 | -3.28 | -72.3 | -8.5 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -184 | -225 | -324 | -456 | -190 |
| Capital Expenditures | -0.209 | -0.217 | -1.48 | -6.46 | -3.47 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -4.85 | 207 | -501 | -268 | 35.8 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -5.05 | 207 | -503 | -274 | 32.3 |
| Financing Cash Flow Items | — | -0.886 | -0.363 | 0 | -10.4 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 171 | 313 | 595 | 735 | 256 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -17.7 | 295 | -232 | 5.1 | 98.8 |